USA: +1 347 690-0211 | UK: +44 2032 894158 | JAPAN: +81 50 5806 9039 | Translate : 

report img

Urinary Tract Infection Therapeutics Market- By Age Group (Children, Adults & Elderly), By Indication (Complicated, Uncomplicated, Recurrent, Catheter-related), By Distribution Network (E-commerce, Hospital Pharmacies, Retail Pharmacies), By Drug Group (Azoles and Amphotericin B, Cephalosporin, Quinolones, Nitrofurans, Penicillin & Combinations, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2021-2027

Covid-19

Global Urinary Tract Infection Therapeutics Market Size, Share

The pandemic continues to cause unprecedented disruption across industries worldwide.Get detailed insights regarding the impact of COVID-19 on the market. Request Sample

Industry Insights

[215+ Pages Research Report] According to Facts and factors, The global Urinary Tract Infection Therapeutics Market was worth about USD 8,935 million in 2020 and is predicted to grow to around USD 11,652 million by 2027, with a compound annual growth rate (CAGR) of around 4.56%. The research includes a global and regional forecast and analysis of the urinary tract infection therapeutics market. It also provides a comprehensive analysis, market growth & forecast, trends, potential drivers, and constraints. In addition, the report examines global opportunities in the urinary tract infection therapeutics market from 2021 to 2027.

logoMarket Overview

Urinary tract infections can affect both the lower and upper urinary tract lines. Bacterial infection has the potential to infect and damage the area. If there is an infection in the urinary tract, pain is common during urination. Urinary infections can be caused by a number of different circumstances. It is an illness that affects a large number of people. However, this virus has a significant death rate. There are certain medications, treatments, and indication segments that generate a lot of interest. Infection can be caused by frequent urination even when the bladder is empty. Obesity and diabetes are two of the most prominent causes of these infections.

The global urinary tract infection therapeutics market is in great demand as the number of cases of UTI is rising constantly. This infection in the urinary tract affects a large percentage of females. This condition affects more than half of the female population. In recent years, 1 million people have been admitted to hospitals due to UTIs. Kidney stones, according to urological developments, are key contributors impacting urological health. Urinary tract infections are more common in patients with renal disease and stones. These factors will result in a high rate of UTI treatments in the coming years.

Urinary Tract Infection Therapeutics Market

logoIndustry Growth Factors

Urinary tract infection can affect kidneys, urethra, bladder, and prostate gland. It is thought that using clean toilets will avoid such diseases. Another element that helps to prevent this infection is maintaining good intimate hygiene. Because of the high prevalence of these infections, UTI therapy is widely used. In addition, the introduction of combination medications is a key factor for market growth.

These infections respond well to combination medications. The availability of such a diverse spectrum of medications is predicted to increase the demand for UTI therapy. The industry is in great demand due to the growing geriatric population, since such infections are very common among the elderly. UTI is a common problem among older women over the age of 65. The UTI treatment industry will benefit from the increase in the elderly population. All of these global urinary tract infection therapeutics market drivers will contribute to its remarkable growth rate.

The market for urinary tract infection therapeutics will expand as new products enter the market. The market's end-user base will grow as a result of innovation and new product releases. The new product also improves the application of urinary tract infection treatment. To effectively cure infections, the leading players are inventing novel therapies and formulations using effective materials. Customers will have a wide selection of treatment options as a result of these upcoming market advances.

Key players are launching medications that break down infectious cells. This advancement will ensure that the patient is not affected by UTI infections in the future. The supply of UTI therapies will increase as a result of this growth factor. Penicillin and combination medications are expected to gain popularity in numerous locations. Furthermore, the leading players are working on new growth tactics. During the projection period, the production of UTI treatment medications will increase dramatically. Many end-users will be attracted to the launch of a wide choice of UTI medicines. All of these things will add to the market's high revenue rates.

logoSegmentation Analysis

The candle market is segmented based on age group, indication, distribution network, drug group, and region:   

As per age group, the urinary tract infection therapeutics market is segmented into Children, Adults & Elderly. On the basis of indication, the market is segregated into Complicated, Uncomplicated, Recurrent, and Catheter-related. Further, the market is divided on the basis of distribution network such as E-commerce, Hospital Pharmacies, and Retail Pharmacies. On the basis of drug group the market is divided into Azoles and Amphotericin B, Cephalosporin, Quinolones, Nitrofurans, Penicillin & Combinations, and Others.

logoReport Scope

Report Attribute

Details

Market Size in 2020

USD 8,935 Million

Projected Market Size in 2027

USD 11,652 Million

CAGR Growth Rate

4.56% CAGR

Base Year

2020

Forecast Years

2021-2027

Key Market Players

Achaogen, Allergen, Aquinox, AstraZeneca, Almirall, S.A, Bayer AG, Bristol-Myers Squibb Company, Cipla, C.H. Boehringer Sohn, Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche, GlaxoSmithKline plc., Janssen Global Services, LLC, Lipella Pharmaceuticals, Lupin Ltd., MediciNova, MerLion Pharmaceuticals, Merck & Co., Inc, Novo Nordisk, Novartis, Pfizer, Sun Pharmaceutical Industries, Shionogi, Teva Pharmaceutical Industries, Urigen, Zavante Therapeutics, and Others

Key Segment

By Age Group, By Indication, By Distribution Network, By Drug Group, and By Region

Major Regions Covered

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Purchase Options

Request customized purchase options to meet your research needs. Explore purchase options

logoRegional Analysis

Diagnostic and innovative treatments will boost growth in North America for the urinary tract infection therapeutics market. In addition, the United States and Canada will make the most investments in UTI treatments. UTI medications are effective in treating serious bacterial infections in the urinary system.

In addition, Asia appeases to be another big competitor with a significant market share. There is an increasing demand for UTI treatment. The expansion of health infrastructure contributes to overall growth. In addition, new product launches will result from developments. In the Asia Pacific, the prevalence of UTIs is greater. Europe is the next greatest region in terms of UTI treatment expansion. The market has a strong growth potential, which will result in new advancements in the coming years.

logoCompetitive Players

The market for global urinary tract infection therapeutics is dominated by a few major competitors. The completion will be intense with new product developments. Major companies in the global market are raising product awareness in a variety of locations. These public awareness campaigns will increase the number of people who use UTI medications. In addition, market acquisitions, growth, and alliances will be prevalent during the projected period.

Major players in the global urinary tract infection therapeutics market are Achaogen, Allergen, Aquinox, AstraZeneca, Almirall, S.A, Bayer AG, Bristol-Myers Squibb Company, Cipla, C.H. Boehringer Sohn, Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche, GlaxoSmithKline plc., Janssen Global Services, LLC, Lipella Pharmaceuticals, Lupin Ltd., MediciNova, MerLion Pharmaceuticals, Merck & Co., Inc, Novo Nordisk, Novartis, Pfizer, Sun Pharmaceutical Industries, Shionogi, Teva Pharmaceutical Industries, Urigen, and Zavante Therapeutics.

The global urinary tract infection therapeutics market is segmented as follows:

logoBy Age Group Segment Analysis

  • Children
  • Adults
  • Elderly

logoBy Indication Segment Analysis

  • Complicated
  • Uncomplicated
  • Recurrent
  • Catheter-related

logoBy Distribution Network Segment Analysis

  • E-Commerce
  • Hospital Pharmacies
  • Retail Pharmacies

logoBy Drug Group Segment Analysis

  • Azoles and Amphotericin B
  • Cephalosporin
  • Quinolones
  • Nitrofurans
  • Penicillin and Combinations
  • Others

logoBy Regional Segment Analysis

  • North America
    • The U.S.
    • Canada
    • Rest of North America
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Southeast Asia
  • The Middle East & Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Kuwait
    • South Africa
    • Rest of Middle East & Africa
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America

Covid-19

Urinary Tract Infection Therapeutics Market

The pandemic continues to cause unprecedented disruption across industries worldwide.Get detailed insights regarding the impact of COVID-19 on the market. Request Sample

Industry Major Market Players

  • Achaogen
  • Allergen
  • Aquinox
  • AstraZeneca
  • Almirall
  • S.A
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cipla
  • C.H. Boehringer Sohn
  • Dr. Reddy’s Laboratories Ltd.
  • F. Hoffmann-La Roche
  • GlaxoSmithKline plc.
  • Janssen Global Services
  • LLC
  • Lipella Pharmaceuticals
  • Lupin Ltd.
  • MediciNova
  • MerLion Pharmaceuticals
  • Merck & Co.Inc
  • Novo Nordisk
  • Novartis
  • Pfizer
  • Sun Pharmaceutical Industries
  • Shionogi
  • Teva Pharmaceutical Industries
  • Urigen
  • Zavante Therapeutics.

Frequently Asked Questions

Urinary tract infection can affect kidneys, urethra, bladder and prostate gland. It is thought that using clean toilets will avoid such diseases. Another element that helps to prevent this infection is maintaining good intimate hygiene. Because of the high prevalence of these infections, UTI therapy is widely used.
According to the Facts and factors, the global urinary tract infection therapeutics market generated worth about USD 8,935 million in 2020 and is predicted to grow to around USD 11,652 million by 2027, with a compound annual growth rate (CAGR) of around 4.56%.
The market for UTI treatment is divided into Asia Pacific, Europe, and North America. Diagnostic treatments that are innovative will boost growth in North America. In addition, Asia appeases another big competitor with significant market share.
Major players in the global urinary tract infection therapeutics market are Achaogen, Allergen, Aquinox, AstraZeneca, Almirall, S.A, Bayer AG, Bristol-Myers Squibb Company, Cupola, C.H. Boehringer Sohn, Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche, GlaxoSmithKline plc., Janssen Global Services, LLC, Lipella Pharmaceuticals, Lupin Ltd., MediciNova, MerLion Pharmaceuticals, Merck & Co., Inc., Novo Nordisk, Novartis, Pfizer, Sun Pharmaceutical Industries, Shionogi, Teva Pharmaceutical Industries, Urigen, Zavante Therapeutics.
why choose fnf
key questions answers

Related Reports

report img

Cold Plasma Market Report 2022-2028

[201+ Pages Report] According to Facts and Factors, the global cold plasma market was worth USD 1.8 billion in 2021 and is expected to grow to USD 3.5 billion by 2028, growing at a 16.2% CAGR between 2022 and 2028. The global cold plasma market report provides a comprehensive analysis of the marke...

Published Date : 11-May-2022 | | Category : | Pages : 201 | Format : Read more

Inquiry for Buying Request Sample
report img

Etanercept Market Report 2022-2028

[221+ Pages Report] According to Facts and Factors, during the forecast period of 2022 to 2028, the global etanercept market is estimated to develop at a compound annual growth rate (CAGR) of 3.3%. The global etanercept market was worth USD 15.5 billion in 2021, and it is anticipated to exceed USD...

Published Date : 26-Apr-2022 | | Category : | Pages : 221 | Format : Read more

Inquiry for Buying Request Sample